{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:59:29Z","timestamp":1790171969627,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Multiple noninvasive scoring models have been internationally established and verified for assessing the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) patients. This study aimed to assess the performance of Fibrosis-4 (FIB-4) Index, NAFLD fibrosis score (NFS), and aspartate aminotransferase-to-platelet ratio index (APRI) in individuals with NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective chart audit of 211 patients with histologically confirmed NAFLD, focusing on clinical presentation, laboratory parameters, and hepatic histology. Liver fibrosis was graded using the Scheuer classification system. The diagnostic accuracy of the noninvasive tests was evaluated, and revised fibrosis score thresholds. These cohort-derived thresholds may help inform local risk stratification in patients with NAFLD, but external validation is required before clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among the cohort, fibrosis was staged as follows: 5.7% showed no fibrosis (F0), 56.9% had mild portal expansion (F1), 21.8% exhibited periportal septa (F2), 10.9% displayed architectural distortion without cirrhosis (F3), and 4.7% presented with definite cirrhosis (F4). After threshold optimization, the FIB-4 and NFS models reached the area under the receiver operating characteristic curve (AUROCs) of 0.81 (95% confidence interval [CI]: 0.743\u20130.867) and 0.79 (95% CI: 0.728\u20130.852) for identifying significant fibrosis, surpassing the 0.70 (95% CI: 0.629\u20130.773) recorded for APRI. Significant differences in the AUROCs were observed among the three scores. Similarly, for advanced fibrosis, FIB-4 (AUROC: 0.91, 95% CI: 0.869\u20130.951) and NFS (AUROC: 0.90, 95% CI: 0.851\u20130.948) significantly outperformed APRI (AUROC: 0.75, 95% CI: 0.672\u20130.837; both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). However, the AUROCs of the three scores were not significantly different in cirrhosis. For fibrosis exclusion, the optimal cutoffs we derived from FIB-4, NFS, and APRI were all lower than the conventional cutoffs while maintaining similar diagnostic accuracy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Modification of the threshold values for FIB-4, NFS, and APRI may enhance the diagnostic performance in patients with NAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jrms.jrms_1084_25","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:00:44Z","timestamp":1790168444000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Fibrosis-4 Index, nonalcoholic fatty liver disease fibrosis score, and aspartate aminotransferase-to-platelet ratio index as noninvasive indicators of fibrosis in patients with nonalcoholic fatty liver disease"],"prefix":"10.4103","volume":"31","author":[{"given":"Mingxi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Shandong Rehabilitation Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Liver Disease, The Second Hospital of Nanjing, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6]]},"reference":[{"key":"R1-20260923","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: A clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"R2-20260923","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"26104","DOI":"10.1038\/s41598-024-77307-8","article-title":"Liver magnetic resonance imaging, non-alcoholic fatty liver disease and metabolic syndrome risk in pre-pubertal Mexican boys","volume":"14","author":"de Celis Alonso","year":"2024","journal-title":"Sci Rep"},{"key":"R5-20260923","first-page":"e70711","article-title":"Point shear wave elastography for assessment of liver stiffness in normal individuals and in patients with non-alcoholic fatty liver disease","volume":"16","author":"Patil","year":"2024","journal-title":"Cureus"},{"key":"R6-20260923","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11547-022-01475-8","article-title":"Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD","volume":"127","author":"Argalia","year":"2022","journal-title":"Radiol Med"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MEG.0000000000002686","article-title":"Association between novel inflammatory markers and non-alcoholic fatty liver disease: A cross-sectional study","volume":"36","author":"Wang","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.21037\/qims-24-148","article-title":"The effectiveness of magnetic resonance imaging (MRI) iron corrected T1 in monitoring metabolic dysfunction-associated steatohepatitis in obesity following bariatric surgery and lifestyle modification: A prospective cohort study","volume":"14","author":"Chiyanika","year":"2024","journal-title":"Quant Imaging Med Surg"},{"key":"R9-20260923","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12876-022-02570-w","article-title":"Accuracy of noninvasive methods for the diagnosis of liver fibrosis in children with chronic viral hepatitis","volume":"22","author":"ElShahawy","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"R10-20260923","first-page":"2206","article-title":"Real-world validation of noninvasive tests","volume":"71","year":"2022","journal-title":"Gut"},{"key":"R11-20260923","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.3390\/diagnostics12102282","article-title":"Noninvasive diagnosis of hepatic fibrosis in hemodialysis patients with hepatitis C virus infection","volume":"12","author":"Liu","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R12-20260923","first-page":"311","article-title":"Validation of the European association for the study of the liver algorithm for noninvasive diagnosis of advanced fibrosis","volume":"13","author":"Kalligeros","year":"2024","journal-title":"Hepatology"},{"key":"R13-20260923","doi-asserted-by":"crossref","first-page":"952","DOI":"10.5009\/gnl210391","article-title":"Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"16","author":"Han","year":"2022","journal-title":"Gut Liver"},{"key":"R14-20260923","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"R15-20260923","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical Bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1007\/s11695-020-04509-0","article-title":"Performance of noninvasive liver fibrosis scores in the morbidly obese patient: Same scores but different thresholds","volume":"30","author":"Meneses","year":"2020","journal-title":"Obes Surg"},{"key":"R17-20260923","first-page":"101011","article-title":"Impact of age on NIS2+\u2122 and other non-invasive blood tests for evaluation of liver disease","volume":"6","author":"Anstee","year":"2024","journal-title":"J Hepatol"},{"key":"R18-20260923","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"R19-20260923","first-page":"100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: An update for the age of artificial intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"R20-20260923","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.4103\/jfmpc.jfmpc_666_21","article-title":"APRI and FIB-4 Performance to Assess Liver Fibrosis against Predefined Fibroscan Values in Chronic Hepatitis C Virus Infection","volume":"10","author":"Rungta","year":"2021","journal-title":"J Family Med Prim Care"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3350\/cmh.2023.0045","article-title":"Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease","volume":"29","author":"Basheer","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R22-20260923","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00592-019-01467-7","article-title":"Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease","volume":"57","author":"Alkayyali","year":"2020","journal-title":"Acta Diabetol"},{"key":"R23-20260923","doi-asserted-by":"crossref","first-page":"e0055","DOI":"10.1097\/HC9.0000000000000055","article-title":"Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: Independent validation of the Agile 3+ and 4 scores","volume":"7","author":"Noureddin","year":"2023","journal-title":"Hepatol Commun"},{"key":"R24-20260923","doi-asserted-by":"crossref","first-page":"e2008","DOI":"10.1210\/clinem\/dgab933","article-title":"Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease","volume":"107","author":"Qadri","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-20260923","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/00325481.2022.2058285","article-title":"Noninvasive fibrosis tools in NAFLD: Validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and hepamet fibrosis score in a Portuguese population","volume":"134","author":"Rigor","year":"2022","journal-title":"Postgrad Med"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_1084_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:00:47Z","timestamp":1790168447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_1084_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jrms.jrms_1084_25","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-10-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}